In the rapidly evolving landscape of advanced biochemistry, the term "peptide" has transcended its traditional associations with basic skincare or fundamental biology. As someone who follows the intersection of machine learning and molecular engineering, I have been closely tracking the progress of Unnatural Products (UNP). Their work represents a paradigm shift in how we conceptualize synthetic molecular structures.
The Innovation B The biobucks of Tuesday's deal with argenx are worth more than six times that of the Merck tie-up, reflecting "the increased depth and ehind UNP Peptide Platforms
UNP has created the first platform to repeatably engineer synthetic macrocyclic peptides, a feat that was once considered nearly impossible in the realm of drug discovery. Unlike standard linear chains, th 1 Jul 2025—Macrocyclicpeptidesare designed to engage complex targets like biologics but pass through cell membranes like small molecule drugs. ese macrocycles are small chains of amino acids that for 23 Jan 2024—A biotech company pairing AI with chemistry to enable the next generation of molecularly targeted therapeutics, today announced a collaboration with Merck.Read more m loops, providing a unique structural rigidity. This design is crucial because macrocyclic peptides are designed to engage complex targets while maintaining the capability to pass through cell membranes, much like small molecule drugs.
From my perspective, the most impressive aspect of their approach is how UNP’s proprietary platform Merck & Co. targets 'high-hanging fruit' in oncology with integrates machine learning and parallel chemistry. By leveraging an AI-based macrocycle discovery platform, they can navigate chemical spaces that were previously deemed "undruggable." This is not just theoretical; the company is a biotech developing orally-delivered macrocyclic peptides that aim to bridge the gap between traditional biologics and small-molecule chemistry.
Strategic Milestones and Industry Impact
The industry has taken significant notice of these devel The biobucks of Tuesday's deal with argenx are worth more than six times that of the Merck tie-up, reflecting "the increased depth and opments. The recent news regarding UNP raising a $45M Series B underscores the confidence investors have in their pipeline. Furthermore, high-profile collaborations demonstrate the tangible value of their research:
* Partnerships: Merck & Co. has signed a deal with Santa Cruz, California–based Unnatural Products (UNP) to develop macrocyclic peptide candidates.
* Expansion: Novartis has entered a strategic licensing agreement with UNP for peptide therapeutics, with potential milestone payments reaching into the billions.
* Immunology: Their work with partners like Argenx highlights the versatility of these molecules in addressing complex disease targets.
Technical Precision: The Case of UNP-6457
One of the most verifiable examples of their success is the molecule known as UNP-6457. In their research, they utilized DNA-encoded cyclic peptide libraries to discover this specific nonapeptide. The data shows it inhibits the MDM2-p53 interaction with an IC50 of 8.9 nM. This level of potency is a testament to the effectiveness of their AI-driven design processes.
Understanding the Landscape
When discussing the broader field, it is important to distinguish between various types of molecules. While many are familiar with basic peptides in consumer products, the macro 23 Jan 2024—Now, Merck has tapped upUNP to apply its tech to develop macrocyclic candidates against a “challenging” undisclosed oncology target. The Read more cyclic peptide therapeutics developed by UNP are in a different league. They are engineering these structures to be orally-delivered macrocy Born out of the Lokey Lab, the field leader in macrocycles,UNP has created the the first platform to repeatably engineer synthetic macrocyclic peptidesat clic peptides, which solves a major hurdle for this class of molecules—bioavailability.
As I look toward the future of this field, it is clear that the combination of machine learning and massively parallel chemistry is unlocking new potential. Whether it is refining the design of cyclic peptide companies or advancing the development of macrocyclic peptide-based therapies, the work being done at UNP is setting a new standard.
The transition from traditional, manual discovery to the AI-augmented synthesis of macrocycles is a fascinating journey to witness. For those of us interested in the cutting edge of molecular science, the progress of UNP serves as a primary example of how innovation can transform our capability to interact with the building blocks of life. By focusing on these specialized loops and structures, the team at UNP is effectively rewriting the rules of what is possible in molecular design.